{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:36:34Z","timestamp":1780371394916,"version":"3.54.1"},"reference-count":37,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2022,3,4]]},"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>An understanding of the experience of patients with progressive fibrosing interstitial lung disease (PF-ILD) is needed to select appropriate patient-reported outcome measures (PROMs) to evaluate treatment effect in clinical trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic literature review was conducted to develop a preliminary conceptual model of the symptoms experienced by patients with PF-ILD and the impacts the disease has on them. An online survey and consensus meetings were then conducted with 12\u201314 stakeholders (patients, clinicians, regulatory and payer advisors) to refine the conceptual model and critically appraise how key concepts should be measured by PROMs. PROMs assessed included Living with Idiopathic Pulmonary Fibrosis, Living with Pulmonary Fibrosis, the King's Brief Interstitial Lung Disease questionnaire, Cough and Sputum Assessment Questionnaire, Evaluating Respiratory Symptoms, Leicester Cough Questionnaire, Functional Assessment of Chronic Illness Therapy (Dyspnoea\/Fatigue) and St George's Respiratory Questionnaire for Idiopathic Pulmonary Fibrosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The literature review identified 36 signs\/symptoms and 43 impacts directly or indirectly related to pulmonary aspects of PF-ILD. The most relevant symptoms identified by participants included shortness of breath on exertion, fatigue and cough; relevant impacts included effects on physical functioning, activities of daily living and emotional wellbeing. These are presented in a conceptual model. Consensus opinion was that existing PROMs need further modification and validation before use in clinical trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The conceptual model improves understanding of the symptoms and impacts that living with PF-ILD has on patients\u2019 wellbeing. It can help to inform the choice of PROMs in clinical trials and highlight aspects to assess in the clinical care of patients with PF-ILD.<\/jats:p><\/jats:sec>","DOI":"10.1183\/23120541.00681-2021","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T16:45:24Z","timestamp":1650559524000},"page":"00681-2021","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures"],"prefix":"10.1183","volume":"8","author":[{"given":"Marlies","family":"Wijsenbeek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Molina-Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chassany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Galvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Hammitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4402-2159","authenticated-orcid":false,"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Moua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5651-8042","authenticated-orcid":false,"given":"Ashley F.","family":"Slagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Krasnow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Reaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Male","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus B.","family":"Rohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Swigris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Antoniou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"key":"2024101711322067000_8.2.00681-2021.1","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases. Reply","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N Engl J Med"},{"key":"2024101711322067000_8.2.00681-2021.2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00692-2018"},{"key":"2024101711322067000_8.2.00681-2021.3","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1007\/s10067-019-04720-0","article-title":"Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases","volume":"38","author":"Fischer","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2024101711322067000_8.2.00681-2021.4","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s12325-020-01578-6","article-title":"Estimation of the prevalence of progressive fibrosing interstitial lung diseases: systematic literature review and data from a physician survey","volume":"38","author":"Olson","year":"2021","journal-title":"Adv Ther"},{"key":"2024101711322067000_8.2.00681-2021.5","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1513\/AnnalsATS.202001-035SD","article-title":"The Pulmonary Fibrosis Foundation patient registry. Rationale, design, and methods","volume":"17","author":"Wang","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"2024101711322067000_8.2.00681-2021.6","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00217614"},{"key":"2024101711322067000_8.2.00681-2021.7","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12989"},{"key":"2024101711322067000_8.2.00681-2021.8","doi-asserted-by":"publisher","DOI":"10.1177\/1753465816686743"},{"key":"2024101711322067000_8.2.00681-2021.9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1164\/rccm.201903-0614PP","article-title":"Comprehensive supportive care for patients with fibrosing interstitial lung disease","volume":"200","author":"Wijsenbeek","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101711322067000_8.2.00681-2021.10","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0075-2018"},{"key":"2024101711322067000_8.2.00681-2021.11","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.202105-1193ST","article-title":"Patient-centered outcomes research in interstitial lung disease: an official American Thoracic Society research statement","volume":"204","author":"Aronson","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101711322067000_8.2.00681-2021.12","unstructured":"US Food & Drug Administration . Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009. www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM193282.pdf Date last accessed: 28 November 2019."},{"key":"2024101711322067000_8.2.00681-2021.13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c2921"},{"key":"2024101711322067000_8.2.00681-2021.14","unstructured":"European Medicines Agency . Guideline on the Clinical Investigations of Medicinal Products for the Treatment of Pulmonary Arterial Hypertension. 2009. www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigations-medicinal-products-treatment-pulmonary-arterial-hypertension_en.pdf Date last accessed: 18 May 2021."},{"key":"2024101711322067000_8.2.00681-2021.15","unstructured":"European Medicines Agency . Guideline on Clinical Investigation of Medicinal Products in the Treatment of Chronic Obstructive Pulmonary Disease (COPD). 2012. www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-chronic-obstructive-pulmonary-disease_en.pdf Date last accessed: 18 May 2021."},{"key":"2024101711322067000_8.2.00681-2021.16","doi-asserted-by":"crossref","first-page":"00145\u20132020","DOI":"10.1183\/23120541.00145-2020","article-title":"The Living with Pulmonary Fibrosis questionnaire in progressive fibrosing interstitial lung disease","volume":"7","author":"Swigris","year":"2021","journal-title":"ERJ Open Res"},{"key":"2024101711322067000_8.2.00681-2021.17","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-201581"},{"key":"2024101711322067000_8.2.00681-2021.18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12931-020-01359-3","article-title":"Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD in idiopathic pulmonary fibrosis","volume":"21","author":"Prior","year":"2020","journal-title":"Respir Res"},{"key":"2024101711322067000_8.2.00681-2021.19","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.139121"},{"key":"2024101711322067000_8.2.00681-2021.20","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1164\/rccm.202002-0415OC","article-title":"Development and initial validation analyses of the Living with Idiopathic Pulmonary Fibrosis questionnaire","volume":"202","author":"Swigris","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101711322067000_8.2.00681-2021.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2008.06.009"},{"key":"2024101711322067000_8.2.00681-2021.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.10.026"},{"key":"2024101711322067000_8.2.00681-2021.23","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.4.339"},{"key":"2024101711322067000_8.2.00681-2021.24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.rmed.2017.11.011","article-title":"Evaluation of a respiratory symptom diary for clinical studies of idiopathic pulmonary fibrosis","volume":"134","author":"Bacci","year":"2018","journal-title":"Respir Med"},{"key":"2024101711322067000_8.2.00681-2021.25","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-014-0124-z"},{"key":"2024101711322067000_8.2.00681-2021.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.06.001"},{"key":"2024101711322067000_8.2.00681-2021.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(96)00274-6"},{"key":"2024101711322067000_8.2.00681-2021.28","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00190710"},{"key":"2024101711322067000_8.2.00681-2021.29","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.chest.2021.05.071","article-title":"How we do it: managing cough in idiopathic pulmonary fibrosis","volume":"160","author":"Wakwaya","year":"2021","journal-title":"Chest"},{"key":"2024101711322067000_8.2.00681-2021.30","unstructured":"US Food & Drug Administration . Methods to Identify What Is Important to Patients & Select, Develop or Modify Fit-for-Purpose Clinical Outcomes Assessments. 2018. www.fda.gov\/media\/116276\/download"},{"key":"2024101711322067000_8.2.00681-2021.31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12890-017-0495-2","article-title":"Physical activity and activity space in patients with pulmonary fibrosis not prescribed supplemental oxygen","volume":"17","author":"Root","year":"2017","journal-title":"BMC Pulm Med"},{"key":"2024101711322067000_8.2.00681-2021.32","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1164\/rccm.201511-2152OC","article-title":"Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis","volume":"194","author":"Russell","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101711322067000_8.2.00681-2021.33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1164\/rccm.202002-0328OC","article-title":"Home monitoring in patients with idiopathic pulmonary fibrosis. A randomized controlled trial","volume":"202","author":"Moor","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101711322067000_8.2.00681-2021.34","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02406-2016"},{"key":"2024101711322067000_8.2.00681-2021.35","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s12931-020-01579-7","article-title":"A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease","volume":"21","author":"Wong","year":"2020","journal-title":"Respir Res"},{"key":"2024101711322067000_8.2.00681-2021.36","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0154-2020"},{"key":"2024101711322067000_8.2.00681-2021.37","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and reliability of the US National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA Oncol"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00681-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:15:17Z","timestamp":1740374117000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00681-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,5,3]]},"published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1183\/23120541.00681-2021"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00681-2021","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}